Clinical Trials Browser

Phase 1/2 × relatlimab × 1 year × Clear all

Melanoma

NCT05255601 2026-02-25

RELATIVITY-069

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01968109 2026-01-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Tumor-Agnostic

Neoplasms by Site

NCT03610711 2025-12-22

REACTION

Phase 1/2 Active not recruiting

21 enrolled

Gastrointestinal

Gastroesophageal Cancer

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03459222 2025-04-02

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

229 enrolled

Advanced Cancer

Clinical Trials

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

RELATIVITY-069

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

REACTION

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread